Search Results
Results found for "Tectonic Therapeutic"
- Session VI | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
particular, drives tumor growth via effects on GBM stem cell self-renewal and metabolism, but also has a therapeutically has been particularly interested in the role adhesion GPCRs play in glioblastoma biology and their therapeutic Javitch1,2 1Departments of Psychiatry and Molecular Pharmacology and Therapeutics, Columbia University , New York, NY 10032; 2Division of Molecular Therapeutics, New York State Psychiatric Institute, New
- University | Dr. GPCR Ecosystem
GPCR University Empowering Scientists to Advance GPCR Biology & Therapeutics 📚 Learn faster. 🤝 Connect players in GPCR pharmacology and learn how agonists and antagonists shape efficacy, signaling, and therapeutic orthosteric drugs and uncover the power of allosteric modulators and kinetic insights to unlock new therapeutic Take the Next Step You're building the future of GPCR therapeutics.
- Ep 164 with Dr. Ian Chronis
Yamina underscores the therapeutic potential of GPR65, especially in the context of cancer immunotherapy , and how understanding receptor activity in acidic microenvironments could unlock new therapeutic strategies
- Session III | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
technology for high-throughput screening of pharmacological compound libraries to identify potential therapeutic "Ana Lilia Moreno Salinas (2), Arturo Mancini (1), Raida Jallouli (2), Richard Leduc (2) (1)Domain Therapeutics Laurent Sabbagh on the web Domain Therapeutics Characterizing hADGRE5/CD97 Activation and Signaling: Domain Therapeutics North America Inc., Montreal, Quebec, Canada 3.
- Ep 169 with Dr. Sokhom Pin
From his early work as a technician at Johns Hopkins Hospital to leading biology at Servo Therapeutics years of drug discovery research in the pharmaceutical industry, where he works mainly on GPCRs as therapeutic He is passionate about mechanistic profiling of therapeutic molecules as well as drug discovery in general
- Ep 82 with Dr. Lauren M. Slosky
protein-coupled receptors (GPCRs) regulate motivated behavior and how these receptors can be targeted for therapeutic distinct signaling pathways with their physiological effects and may serve as the basis for more selective therapeutics
- Ep 121 with Yao Lu (Jackie)
molecular explanation of small molecules for their pre-clinical efficacy and to support the design of novel therapeutics
- irreversible drugs post 1 | Dr. GPCR Ecosystem
How target depletion and replenishment kinetics define the therapeutic window.
- Ep 05 with Dr. Terry Hébert
Terry Hébert is a Professor within the Department of Pharmacology & Therapeutics at McGill University
- Ep 119 with Tanishka S. Saraf
Saraf " My research focuses on evaluating and targeting serotonin 1A receptors for therapeutic outcomes
- Ep 144 with Dr Aurélien Rizk
the company's ability to predict the residence time of a ligand and its potential correlation with a therapeutic Therapeutic Effect and Receptor Interactions Aurelien Rizk and Yamina had a detailed discussion about the importance of gaining more information about the therapeutic effect in patients or animals and the They also shared their preference for small molecule therapies over protein therapeutics.
- Ep 83 with Dr. Jean-Philippe Pin
biosensors, cryo-EM, photoswitchable ligands, and nanobodies as pharmacological tools and potential therapeutic
- Developing a PROTAC to Degrade the Constitutively Active Onco-GPCR in Uveal Melanoma
of GPCRs in disease states to help test the feasibility of using protein-targeted degradation as a therapeutic
- Celtarys Research | Dr. GPCR Ecosystem
One of the best tools to study therapeutic targets are fluorescent ligands, which are very useful in Celtarys’ cutting-edge fluorescent ligand technology and accelerate the development of GPCR-targeted therapeutics accelerate the adoption of our chemical tools and foster collaborations that turn receptor biology into therapeutic
- irreversible drugs post 2 | Dr. GPCR Ecosystem
The result: inconsistent exposure, patchy activity, and sometimes, outright therapeutic failure.
- Dr. GPCR Symposia | Dr. GPCR Ecosystem
Activation and Signaling March 15th, 2024 GPCRs in Immunology and Oncology November 17, 2023 GPCRs as Therapeutic
- Dopamine-Mediated Motor Recovery after Ischemic Stroke
We hope our research will aid in the development of new therapeutic interventions for the alleviation
- GPCR Retreat Logo Contest | Dr. GPCR Ecosystem
embody the multifaceted nature of GPCRs, showcasing their complexity, versatility, and potential for therapeutic
- Ep 13 with Dr. Amynah Pradhan
Andrew Charles that who specialized in animal models of migraine and delta-opioid receptors as a therapeutic
- Illuminating Functional Selectivity and Allosterism at GPCRs.
He is also an Associate Leader of the Experimental Therapeutics and Metabolism Program and the Director
- Ep 19 with Dr. Fiona Marshall
As a co-founder of Heptares Therapeutics , now called Sosei Heptares , a GPCR-focused drug discovery
- Ep 157 with Dr. Nagarajan Vaidehi
She has advanced the use of computational methods to meet the challenges of designing therapeutics with
- Ep 59 with Dr. Nicola J. Smith
orphan GPCRs from ‘locked’, inaccessible receptors to well-characterized and understood ‘unlocked’ therapeutic
- Ep 35 with Dr. Brian Arey
His recently published book on signaling bias, Biased Signaling in Physiology, Pharmacology, and Therapeutics
- Ep 16 with Dr. Aaron Sato
record as a biologics leader as he led teams to discover and develop novel first-in-class antibody therapeutics
- Ep 34 with Dr. Brian Arey
His recently published book on signaling bias, Biased Signaling in Physiology, Pharmacology, and Therapeutics
- Ep 80 with Dr. Andrew Tobin
vehicle by which Andrew is translating fundamental findings to commercial products is Keltic Pharma Therapeutics
- Targeting adenosine signaling for immuno-oncology
clinical stage company developing next generation immunotherapies, and member of the SAB of Domain Therapeutics
- Ep 31 with Dr. Kevin Pfleger
Institute of Medical Research, Deputy Director of the Australian Research Council Centre for Personalised Therapeutics
- Ep 56 with Dr. Adriano Marchese
The ultimate goal of Adriano’s research is to target novel aspects of GPCR signaling for therapeutic
























